These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 17029774)
1. Aberrant methylation of the 8p22 tumor suppressor gene DLC1 in renal cell carcinoma. Zhang Q; Ying J; Zhang K; Li H; Ng KM; Zhao Y; He Q; Yang X; Xin D; Liao SK; Tao Q; Jin J Cancer Lett; 2007 May; 249(2):220-6. PubMed ID: 17029774 [TBL] [Abstract][Full Text] [Related]
2. The major 8p22 tumor suppressor DLC1 is frequently silenced by methylation in both endemic and sporadic nasopharyngeal, esophageal, and cervical carcinomas, and inhibits tumor cell colony formation. Seng TJ; Low JS; Li H; Cui Y; Goh HK; Wong ML; Srivastava G; Sidransky D; Califano J; Steenbergen RD; Rha SY; Tan J; Hsieh WS; Ambinder RF; Lin X; Chan AT; Tao Q Oncogene; 2007 Feb; 26(6):934-44. PubMed ID: 16862168 [TBL] [Abstract][Full Text] [Related]
3. [Aberrant methylation of tumor suppressor genes in renal cell carcinoma]. Zhang Q; Jin J; Tao Q Ai Zheng; 2007 Nov; 26(11):1276-80. PubMed ID: 17991333 [TBL] [Abstract][Full Text] [Related]
4. Identification of the deleted in liver cancer 1 gene, DLC1, as a candidate meningioma tumor suppressor. Hankins GR; Sasaki T; Lieu AS; Saulle D; Karimi K; Li JZ; Helm GA Neurosurgery; 2008 Oct; 63(4):771-80; discussion 780-1. PubMed ID: 18981889 [TBL] [Abstract][Full Text] [Related]
5. Methylation-associated silencing of TU3A in human cancers. Awakura Y; Nakamura E; Ito N; Kamoto T; Ogawa O Int J Oncol; 2008 Oct; 33(4):893-9. PubMed ID: 18813805 [TBL] [Abstract][Full Text] [Related]
6. Aberrant promoter methylation of DLEC1, a critical 3p22 tumor suppressor for renal cell carcinoma, is associated with more advanced tumor stage. Zhang Q; Ying J; Li J; Fan Y; Poon FF; Ng KM; Tao Q; Jin J J Urol; 2010 Aug; 184(2):731-7. PubMed ID: 20639048 [TBL] [Abstract][Full Text] [Related]
7. Methylation-associated silencing of SFRP1 in renal cell carcinoma. Awakura Y; Nakamura E; Ito N; Kamoto T; Ogawa O Oncol Rep; 2008 Nov; 20(5):1257-63. PubMed ID: 18949430 [TBL] [Abstract][Full Text] [Related]
8. Epigenetic inactivation of the candidate tumor suppressor gene HOXB13 in human renal cell carcinoma. Okuda H; Toyota M; Ishida W; Furihata M; Tsuchiya M; Kamada M; Tokino T; Shuin T Oncogene; 2006 Mar; 25(12):1733-42. PubMed ID: 16278676 [TBL] [Abstract][Full Text] [Related]
9. Genetic and epigenetic control of UNC5C expression in human renal cell carcinoma. Lv D; Zhao W; Dong D; Qian XP; Zhang Y; Tian XJ; Zhang J Eur J Cancer; 2011 Sep; 47(13):2068-76. PubMed ID: 21600761 [TBL] [Abstract][Full Text] [Related]
10. Promoter methylation of the DLC‑1 gene and its inhibitory effect on human colon cancer. Dai Z; Jin Y Oncol Rep; 2013 Sep; 30(3):1511-7. PubMed ID: 23783552 [TBL] [Abstract][Full Text] [Related]
11. Tumor-specific methylation of the 8p22 tumor suppressor gene DLC1 is an epigenetic biomarker for Hodgkin, nasal NK/T-cell and other types of lymphomas. Ying J; Li H; Murray P; Gao Z; Chen YW; Wang Y; Lee KY; Chan AT; Ambinder RF; Srivastava G; Tao Q Epigenetics; 2007; 2(1):15-21. PubMed ID: 17965626 [TBL] [Abstract][Full Text] [Related]
12. RASSF1A promoter methylation and expression analysis in normal and neoplastic kidney indicates a role in early tumorigenesis. Peters I; Rehmet K; Wilke N; Kuczyk MA; Hennenlotter J; Eilers T; Machtens S; Jonas U; Serth J Mol Cancer; 2007 Jul; 6():49. PubMed ID: 17634119 [TBL] [Abstract][Full Text] [Related]
13. Wnt antagonist family genes as biomarkers for diagnosis, staging, and prognosis of renal cell carcinoma using tumor and serum DNA. Urakami S; Shiina H; Enokida H; Hirata H; Kawamoto K; Kawakami T; Kikuno N; Tanaka Y; Majid S; Nakagawa M; Igawa M; Dahiya R Clin Cancer Res; 2006 Dec; 12(23):6989-97. PubMed ID: 17145819 [TBL] [Abstract][Full Text] [Related]
14. Imprinted DLK1 is a putative tumor suppressor gene and inactivated by epimutation at the region upstream of GTL2 in human renal cell carcinoma. Kawakami T; Chano T; Minami K; Okabe H; Okada Y; Okamoto K Hum Mol Genet; 2006 Mar; 15(6):821-30. PubMed ID: 16439445 [TBL] [Abstract][Full Text] [Related]
15. Inactivation of BHD in sporadic renal tumors. Khoo SK; Kahnoski K; Sugimura J; Petillo D; Chen J; Shockley K; Ludlow J; Knapp R; Giraud S; Richard S; Nordenskjöld M; Teh BT Cancer Res; 2003 Aug; 63(15):4583-7. PubMed ID: 12907635 [TBL] [Abstract][Full Text] [Related]
16. Aberrant methylation of RASGRF2 and RASSF1A in human non-small cell lung cancer. Chen H; Suzuki M; Nakamura Y; Ohira M; Ando S; Iida T; Nakajima T; Nakagawara A; Kimura H Oncol Rep; 2006 May; 15(5):1281-5. PubMed ID: 16596198 [TBL] [Abstract][Full Text] [Related]
17. [Methylation of the promoter region of the RASSF1A gene, a candidate tumor suppressor, in primary epithelial tumors]. Loginov VI; Maliukova AV; Seregin IuA; Khodyrev DS; Kazubskaia TP; Ermilova VD; Gar'kavtseva RF; Kiselev LL; Zabarovskiĭ ER; Braga EA Mol Biol (Mosk); 2004; 38(4):654-67. PubMed ID: 15456137 [TBL] [Abstract][Full Text] [Related]
18. Aberrant promoter hypermethylation and silencing of the critical 3p21 tumour suppressor gene, RASSF1A, in Chinese oesophageal squamous cell carcinoma. Wong ML; Tao Q; Fu L; Wong KY; Qiu GH; Law FB; Tin PC; Cheung WL; Lee PY; Tang JC; Tsao GS; Lam KY; Law S; Wong J; Srivastava G Int J Oncol; 2006 Mar; 28(3):767-73. PubMed ID: 16465383 [TBL] [Abstract][Full Text] [Related]
19. Frequent epigenetic inactivation of RASSF1A by aberrant promoter hypermethylation in human gastric adenocarcinoma. Byun DS; Lee MG; Chae KS; Ryu BG; Chi SG Cancer Res; 2001 Oct; 61(19):7034-8. PubMed ID: 11585730 [TBL] [Abstract][Full Text] [Related]